Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Sleep Medicine

Restoring Wakefulness: Standard Treatments for Narcolepsy Type 2

At a Glance

Narcolepsy type 2 is usually managed with an individualized combination of wakefulness-promoting medication, planned short naps, regular sleep, and safety planning. Doctors consider blood pressure, mental health, kidney function, other medicines, and nighttime sleep when choosing treatment.

Managing Narcolepsy Type 2 (NT2) is a highly personalized process. Unlike Type 1, where the focus includes stopping muscle weakness (cataplexy), the primary goal in NT2 is to manage excessive daytime sleepiness (EDS) and improve your daily function [1][2].

Current clinical guidelines from the American Academy of Sleep Medicine (AASM) and the European Academy of Neurology (EAN) support several pharmacologic options alongside lifestyle strategies, with individualized selection [1][3].

Non-Drug Strategies as Adjuncts

Alongside medication, standard care involves specific behavioral changes that can help maximize your alertness:

  • Scheduled Naps: One or two brief, planned naps (15–20 minutes) during the day are recommended. These “tactical naps” may provide a temporary alertness benefit, though duration and refreshment vary from person to person. Naps are an adjunct, not a substitute for medical treatment, and longer or poorly timed naps can cause sleep inertia (grogginess) [1][3].
  • Sleep Hygiene: Maintaining a very consistent sleep-wake schedule helps stabilize your brain’s internal clock [3][4].
  • Safety Planning: This includes identifying “high-risk” times for sleepiness and planning activities like driving or important meetings around your most alert periods [4].

Guideline-Supported Medication Options

The medications used for NT2 target excessive daytime sleepiness. Treatments specifically for cataplexy are not typically prescribed for NT2 unless that symptom develops later [2][5]. Medication choice is tailored to your symptoms, comorbidities, tolerability, and potential drug interactions.

Wakefulness Promoters

  • Modafinil and Armodafinil: These are designed to keep the brain in a “wake” state [6]. Common side effects include headache, nausea, anxiety, and insomnia [7].
    • Important Note: These can reduce the effectiveness of hormonal contraceptives (birth control pills/patches/implants). You must follow the current product label and prescriber guidance, which often requires alternative or additional non-hormonal protection during and for a period after treatment [8][9].
  • Solriamfetol: This medication targets dopamine and norepinephrine to promote wakefulness [10]. Because it can increase blood pressure and heart rate, doctors will monitor these regularly [11]. Dosage adjustments are needed if you have kidney issues [12].
  • Pitolisant: This works by increasing histamine in the brain to keep you alert [13]. It can affect the heart’s electrical conduction (QT interval) and has drug interaction considerations. Like modafinil, it can also interfere with hormonal birth control [14].

Nighttime Treatments for Daytime Alertness

  • Sodium Oxybate and Low-Sodium Oxybate: These are potent central nervous system (CNS) depressants taken in a specific nighttime regimen [15]. While they consolidate sleep, their primary benefit for NT2 is reducing sleepiness the following day [16].
    • Low-Sodium Oxybate reduces the sodium load (by 92%) for those with cardiovascular risks, but it does not remove the CNS-depressant risks [17][18].
    • Major Safety Warnings: Oxybates carry risks of respiratory depression and misuse. They must be dispensed through secure handling programs (such as REMS). They must never be mixed with alcohol, opioids, benzodiazepines, sleep medicines, or other CNS depressants, as the combination can be life-threatening [19][20]. You must discuss sleep apnea or any breathing disorders with your specialist before starting.

Individualizing Your Care

Because there is no “best” medication for everyone, your doctor will choose a treatment based on your specific health profile:

  • Cardiovascular Risk: If you have high blood pressure, your doctor may consider the risks of solriamfetol or prefer a low-sodium version of oxybate [11][17].
  • Mental Health: If you have a history of anxiety or mood disorders, certain stimulants may worsen those symptoms [7][21].
  • Lifestyle and Routine: Your primary daytime goals and nighttime awakenings help dictate whether a daytime wakefulness promoter or a nighttime oxybate is most appropriate [15][22].

The goal of treatment is to reduce your sleepiness enough so that you can live your life safely and fully.

Common questions in this guide

What is the usual treatment approach for narcolepsy type 2?
Treatment usually combines a medicine that promotes daytime wakefulness with brief planned naps, a regular sleep schedule, and safety planning. The goal is to reduce excessive daytime sleepiness and improve daily function, but the best combination differs from person to person.
Which medicines are used for daytime sleepiness in NT2?
Options include modafinil, armodafinil, solriamfetol, pitolisant, and sodium or low-sodium oxybate. A clinician chooses among them based on your blood pressure, heart health, kidney function, anxiety or mood history, nighttime sleep, and possible drug interactions.
Can planned naps help with narcolepsy type 2?
One or two planned naps lasting about 15 to 20 minutes may provide a temporary alertness benefit, although the effect varies. Longer or poorly timed naps can cause sleep inertia, so naps support medical treatment rather than replace it.
Can narcolepsy type 2 medicines affect hormonal birth control?
Modafinil and armodafinil can reduce the effectiveness of hormonal contraceptives, and pitolisant may also interfere with them. Ask your prescriber about the current product label and whether you need alternative or additional nonhormonal protection during treatment and for the recommended period afterward.
What safety concerns come with sodium oxybate or low-sodium oxybate?
These medicines slow the central nervous system and can cause dangerously slow breathing or misuse, so they are dispensed through a secure handling program. Never combine them with alcohol, opioids, benzodiazepines, sleep medicines, or other central nervous system depressants, and tell your specialist about sleep apnea or other breathing problems before starting.
How will my doctor choose the safest narcolepsy type 2 treatment?
Your doctor may consider your blood pressure and cardiovascular health, kidney function, anxiety or mood history, nighttime awakenings, current medicines, and daily goals. For example, solriamfetol can raise blood pressure and heart rate and may require a kidney-related dose adjustment, while oxybate requires review of breathing disorders and other sedating medicines.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my blood pressure and cardiovascular health, which of these medications would be the safest option for me?
  2. 2.If I use hormonal contraception, how will modafinil or pitolisant affect its effectiveness?
  3. 3.Given that I don't have cataplexy, is an oxybate (which treats both sleepiness and cataplexy) a better or worse choice than a daytime-only stimulant for my specific case?
  4. 4.How should my kidney function be monitored if we decide on solriamfetol?
  5. 5.If my nighttime sleep is very fragmented, which of these treatments is most likely to help me stay asleep while also improving my daytime alertness?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    European guideline and expert statements on the management of narcolepsy in adults and children.

    Bassetti CLA, Kallweit U, Vignatelli L, et al.

    Journal of sleep research 2021; (30(6)):e13387 doi:10.1111/jsr.13387.

    PMID: 34173288
  2. 2

    Management of Narcolepsy.

    Barateau L, Lopez R, Dauvilliers Y

    Current treatment options in neurology 2016; (18(10)):43 doi:10.1007/s11940-016-0429-y.

    PMID: 27549768
  3. 3

    Narcolepsy: an interface among neurology, immunology, sleep, and genetics.

    Coelho FMS

    Arquivos de neuro-psiquiatria 2024; (82(6)):1-9 doi:10.1055/s-0044-1779299.

    PMID: 38565187
  4. 4

    [Pharmacological and non-pharmacological treatment for narcolepsy].

    Gorbachev NA, Balabanova MA, Poluektov MG

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2026; (126(5. Vyp. 2)):55-62 doi:10.17116/jnevro202612605255.

    PMID: 42268273
  5. 5

    Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy.

    Black J, Swick T, Bogan R, et al.

    Sleep medicine 2016; (24()):57-62 doi:10.1016/j.sleep.2016.07.010.

    PMID: 27810187
  6. 6

    Treatment of Excessive Daytime Sleepiness in Patients with Narcolepsy.

    Pérez-Carbonell L

    Current treatment options in neurology 2019; (21(11)):57 doi:10.1007/s11940-019-0595-9.

    PMID: 31713736
  7. 7

    Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects.

    Sousa A, Dinis-Oliveira RJ

    Substance abuse 2020; (41(2)):155-173 doi:10.1080/08897077.2019.1700584.

    PMID: 31951804
  8. 8

    Samelisant (SUVN-G3031), a histamine H3 receptor inverse agonist, as a potential treatment for narcolepsy: a phase-2 drug evaluation.

    Nirogi R, Shinde A, Subramanian R, et al.

    Expert opinion on investigational drugs 2026; (35(3)):203-210 doi:10.1080/13543784.2026.2634990.

    PMID: 41725284
  9. 9

    Evaluation of pitolisant, sodium oxybate, solriamfetol, and modafinil for the management of narcolepsy: a retrospective analysis of the FAERS database.

    Zhou X, Chen J, Xu B, Chen L

    Frontiers in pharmacology 2024; (15()):1415918 doi:10.3389/fphar.2024.1415918.

    PMID: 39588154
  10. 10

    Update on Persistent Excessive Daytime Sleepiness in OSA.

    Javaheri S, Javaheri S

    Chest 2020; (158(2)):776-786 doi:10.1016/j.chest.2020.02.036.

    PMID: 32147246
  11. 11

    New pharmacologic agents for insomnia and hypersomnia.

    Earl DC, Van Tyle KM

    Current opinion in pulmonary medicine 2020; (26(6)):629-633 doi:10.1097/MCP.0000000000000722.

    PMID: 32890017
  12. 12

    Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis.

    Zomorodi K, Chen D, Lee L, et al.

    Journal of clinical pharmacology 2019; (59(8)):1120-1129 doi:10.1002/jcph.1402.

    PMID: 30865315
  13. 13

    A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor.

    Carter LP, Henningfield JE, Wang YG, et al.

    Journal of psychopharmacology (Oxford, England) 2018; (32(12)):1351-1361 doi:10.1177/0269881118796814.

    PMID: 30269642
  14. 14

    Drug Interactions With Excessive Daytime Sleepiness Treatments.

    Thomas SV, Malesker MA, Hilleman DE, Dewan NA

    The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians 2025; 87551225251369328 doi:10.1177/87551225251369328.

    PMID: 41054740
  15. 15

    Calcium, Magnesium, Potassium and Sodium Oxybates (Xywav®) in Sleep Disorders: A Profile of Its Use.

    Heo YA

    CNS drugs 2022; (36(5)):541-549 doi:10.1007/s40263-022-00912-6.

    PMID: 35357671
  16. 16

    Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline.

    Maski K, Trotti LM, Kotagal S, et al.

    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2021; (17(9)):1881-1893 doi:10.5664/jcsm.9328.

    PMID: 34743789
  17. 17

    Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia.

    Junnarkar G, Allphin C, Profant J, et al.

    Expert opinion on drug discovery 2022; (17(2)):109-119 doi:10.1080/17460441.2022.1999226.

    PMID: 34818123
  18. 18

    Effects of High- Versus Low-Sodium Oxybate on Blood Pressure in Patients With Narcolepsy.

    White WB, Kovacs RJ, Alexander JK, et al.

    Hypertension (Dallas, Tex. : 1979) 2025; (82(12)):2162-2171 doi:10.1161/HYPERTENSIONAHA.125.25730.

    PMID: 41090230
  19. 19

    γ-Hydroxybutyric Acid: Pharmacokinetics, Pharmacodynamics, and Toxicology.

    Felmlee MA, Morse BL, Morris ME

    The AAPS journal 2021; (23(1)):22 doi:10.1208/s12248-020-00543-z.

    PMID: 33417072
  20. 20

    Acute Sodium Oxybate Intoxication: A Case Report and Review of the Literature.

    Drevin G, Briet M, Ferec S, et al.

    Therapeutic drug monitoring 2023; (45(2)):277-281 doi:10.1097/FTD.0000000000001011.

    PMID: 35914751
  21. 21

    Modafinil-associated psychosis: a systematic review of case characteristics and management strategies.

    Sato Y, Sakuma A, Tomita H

    Therapeutic advances in psychopharmacology 2026; (16()):20451253261446554 doi:10.1177/20451253261446554.

    PMID: 42137740
  22. 22

    Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy.

    Bogan RK, Thorpy MJ, Dauvilliers Y, et al.

    Sleep 2021; (44(3)) doi:10.1093/sleep/zsaa206.

    PMID: 33184650

This page is for informational purposes only and does not constitute medical advice. A sleep specialist can help you choose a narcolepsy type 2 treatment based on your health, medications, and safety needs.

Get notified when new evidence is published on Narcolepsy type 2.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.